Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -45

Zoetis (ZTS) Stock Price Drops After Q3 Earnings Margin Pressure

Earnings report Guidance lowered AI-generated analysis

πŸ“‰ Zoetis shares dropped about 3% immediately after Q3 2026 earnings, driven by a sharp decline in profitability and softer full-year guidance.

πŸ’° Quarterly net income excluding extra items fell to US$591 million, representing an 18.0% year-over-year decrease compared to US$721 million last year.

πŸ“Š Basic EPS declined to US$1.44 from US$1.63 in the prior year, marking an 11.8% drop that contributed to the negative market reaction.

πŸ“‰ Adjusted gross margins compressed to approximately 71%, reflecting an operational decline of about 0.6 percentage points year over year.

🐾 Companion animal revenue fell 5% overall, with dermatology sales specifically dropping 16% despite improved guidance for that segment.

πŸ”¬ Diversification efforts showed mixed results as livestock revenue climbed 7% and diagnostics rose 13% to partially offset companion animal weakness.

βš–οΈ Adjusted net income declined 7% organically, indicating that flat operating costs were not enough to counteract the revenue headwinds.

πŸš€ Management stated that scaling new products is essential to offset competitive and pricing pressure in U.S. companion animal therapies.

πŸ’Š The company must convert its broad pipeline in areas like renal disease, oncology, and cardiology into products to replace lost share from existing cash engines.

⚠️ Bearish analysts remain concerned that offsets from growing segments are not yet large enough to neutralize the pressures facing the core business.

Bullish Signals
  • Livestock revenue climbed 7% year over year, demonstrating continued momentum in a key diversified segment.
  • Diagnostics sales rose 13%, providing an additional growth vector to support overall revenue stability.
  • Operating costs remained flat on an adjusted basis, showing that the company is maintaining cost discipline despite market challenges.
Risk Factors
  • Quarterly net income excluding extra items dropped significantly to US$591 million, down 18.0% from the prior year.
  • Adjusted gross margins compressed by approximately 0.6 percentage points year over year to reach about 71%.
  • Companion animal revenue fell 5%, with dermatology sales specifically plunging 16% due to competitive pressure.
  • Adjusted net income declined 7% organically, indicating that current cost controls are insufficient to bridge the profitability gap.
Full Analysis
Zoetis (ZTS) shares dropped approximately 3% on the first trading day following its Q3 2026 earnings release, as investors reacted to significant pressure on profitability and softer full-year guidance. Quarterly net income excluding extra items fell to US$591 million from US$721 million in the prior year, while basic EPS declined to US$1.44 from US$1.63. The market's sharp reaction reflects concerns that the company's steady franchise status is being challenged by recent financial headwinds. The core issue driving the stock decline is a compression in adjusted gross margins, which stood at approximately 71% and represented an operational decline of about 0.6 percentage points year over year. Despite flat operating costs on an adjusted basis, Zoetis saw its adjusted net income decline by 7% organically. This divergence highlights that cost control measures alone are insufficient to bridge the gap created by revenue softness in key segments. Zoetis faces specific headwinds in its companion animal business, where total revenue fell 5% and dermatology sales plummeted 16%. Management emphasizes the critical need to offset competitive pressure and pricing issues in U.S. companion animal therapies by scaling new products and maintaining momentum in livestock and diagnostics. While these latter segments showed growth with livestock up 7% and diagnostics rising 13%, they have not yet been large enough to neutralize the broader pressures affecting the company's bottom line.